earnings
confidence high
sentiment positive
materiality 0.85
Vertex Q2 product revenues $1.79B (+18% YoY); raises FY 2021 guidance to $7.2-7.4B
VERTEX PHARMACEUTICALS INC / MA
2021-Q2 EPS reported
$2.75
revenue$3,517,675,000
- Product revenues $1.793B, up 18% YoY; TRIKAFTA/KAFTRIO $1.256B led growth.
- GAAP net income $67M ($0.26 diluted EPS); non-GAAP net income $811M ($3.11 EPS).
- Raised full-year 2021 product revenue guidance to $7.2-7.4B from $6.7-6.9B.
- Recorded $900M payment to CRISPR in Q2 as R&D expense, impacting GAAP results.
- CTX001 dosed >45 patients; target enrollment in Phase 3 studies expected Q3 2021.